Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster lunch

1349 - Next-generation sequencing of circulating tumor cells isolated from peripheral blood of patients with head and neck and gastrointestinal cancer (545P)


18 Nov 2017


Poster lunch


Kaoru Onidani


Annals of Oncology (2017) 28 (suppl_10): x170-x172. 10.1093/annonc/mdx678


K. Onidani1, Y. Seiichi2, N. Miura1, H. Shoji3, K. Kato3, T. Shibahara4, K. Honda1

Author affiliations

  • 1 Division Of Early Detection For Cancer, National Cancer Center Research Institute, 104-0045 - Tokyo/JP
  • 2 Department Of Head And Neck Oncology, National Cancer Center Hospital, 104-0045 - Tokyo/JP
  • 3 Gastrointestinal Medical Oncology Division, National Cancer Center Hospital, 104-0045 - Tokyo/JP
  • 4 Department Of Oral And Maxillofacial Surgery, Tokyo Dental College, Tokyo/JP


Abstract 1349


Recently, precision medicine has gained attention for the prediction of therapeutic strategies in individual patients. Because the biological behavior of tumor cells has changed over time according to the pressures from treatment, real-time monitoring of tumor biology is needed to provide suitable information for choosing the most effective therapy for each patient. Circulating tumor cells (CTCs) can reflect current tumor status from primary sites and metastases from the bloodstream without invasive testing. In the current CTCs capture platforms of flow cytometry, gradient centrifugation, filtration, and droplets have been employed. A novel label-free inertial microfluidics approach (MFA) based on biomechanical properties has been developed at National Singapore University (Hou et al, Sci Rep 2013), and is able to capture CTCs independent of EpCAM expression. To identify genomic alterations in CTCs as basic data for precision medicine, we investigated the genomic profiling of CTCs using next-generation sequencing (NGS).


Participants in this prospective study comprised 31 patients with advanced head and neck cancer (HN), esophageal cancer (EC), gastric cancer (GC), or colorectal cancer (CRC). CTCs were isolated using an MFA technique from 5 ml of whole blood. NGS was performed after whole-genome amplification (WGA) of DNA extracted from CTCs.


The underlying pathology was HN in 11 patients, EC in 8 patients, GC in 1 patient, and CRC in 11 patients. CTCs were detected from the peripheral blood of all patients (median number of CTCs, 14.5/ml; range, 3-133/ml). The most frequently detected mutations in CTCs were to APC, EGFR, RB1 and SMAD4 (10.5%) in HN and EC, and TP53 (27.2%), MET, RB1, and SMAD4 (18.2%) in CRC. NGS was successfully performed using WGA-treated DNA from CTCs and related material.


We were able to effectively capture CTCs from patients with HN, EC, GC and CRC, and successfully performed NGS of CTCs using a microfluidic separation system without antibodies. Another trial is now ongoing to assess correlations between emergence of gene mutations in CTCs and changes in therapeutic effect during molecular-targeted therapy.

Clinical trial identification

Legal entity responsible for the study

Division of Early Detection for Cancer, National Cancer Center Research Institute




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.